Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialSandro Pignata, I. L. Ray-Coquard, Alessandra Bologna et al.|The Lancet Oncology|2021Cited by 148
Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III DiseaseMaria Vittoria Dieci, Valentina Guarneri, Vassilena Tsvetkova et al.|Frontiers in Oncology|2019Cited by 71
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective studyTommaso Giarratano, Maria Vittoria Dieci, Simona Frezzini et al.|The Breast Journal|2019Cited by 25
Abstract P6-18-24: Lapatinib-based therapies after pertuzumab and/or T-DM1 for HER2+ metastatic breast cancer patientsSimona Frezzini, Valentina Guarneri, Tommaso Giarratano et al.|Cancer Research|2019Cited by 0
Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): A propensity score-matched studyMaria Vittoria Dieci, Tania Saibene, Carlo Alberto Giorgi et al.|Annals of Oncology|2019Cited by 0